LILRB1 and lymphoma: In an effort to analyze the potential of LILRB1 and CD47 co-blockade to enhance the ADCP activity also of lymphoma-associated macrophages (LAM), MNC were prepared from BM samples from DLBCL patients with BM infiltration (Figure 5).